Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 27, 2022

SELL
$2.11 - $3.15 $8,971 - $13,393
-4,252 Closed
0 $0
Q1 2022

Apr 21, 2022

BUY
$3.0 - $4.88 $12,756 - $20,749
4,252 New
4,252 $13,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Riverview Trust CO Portfolio

Follow Riverview Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Riverview Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Riverview Trust CO with notifications on news.